Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review

Michele Fornaro,1 Domenico De Berardis,2 Ann Sarah Koshy,3 Giampaolo Perna,4 Alessandro Valchera,5 Davy Vancampfort,6 Brendon Stubbs7,8 1New York Psychiatric Institute, Columbia University, New York, NY, USA; 2National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, Stubbs B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Bipolar Disorder polypharmacy prevalence systematic review. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0df8bd7f872d402b8a8f7a83207cb815
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0df8bd7f872d402b8a8f7a83207cb815
record_format	dspace
spelling	oai:doaj.org-article:0df8bd7f872d402b8a8f7a83207cb8152021-12-02T02:53:35ZPrevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review1178-2021https://doaj.org/article/0df8bd7f872d402b8a8f7a83207cb8152016-03-01T00:00:00Zhttps://www.dovepress.com/prevalence-and-clinical-features-associated-with-bipolar-disorder-poly-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Michele Fornaro,1 Domenico De Berardis,2 Ann Sarah Koshy,3 Giampaolo Perna,4 Alessandro Valchera,5 Davy Vancampfort,6 Brendon Stubbs7,8 1New York Psychiatric Institute, Columbia University, New York, NY, USA; 2National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, Teramo, Italy; 3St. John’s National Academy of Health Sciences, Bangalore, India; 4Department of Clinical Neurosciences, Hermanas Hospitalarias - Villa San Benedetto Menni Hospital, FoRiPsi, 5Hermanas Hospitalarias, FoRiPsi Villa S. Giuseppe Hospital, Ascoli Piceno, Italy; 6Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium; 7Physiotherapy Department, South London and Maudsley NHS Foundation Trust, 8Health Service and Population Research Department, Institute of Psychiatry, King’s College London, London, UK Background: Uncertainty exists regarding the prevalence and clinical features associated with the practice of polypharmacy in bipolar disorder (BD), warranting a systematic review on the matter.Methods: Three authors independently searched major electronic databases from inception till September 2015. Articles were included that reported either qualitative or quantitative data about the prevalence and clinical features associated with polypharmacy in adult cases of BD.Results: The operative definitions of polypharmacy adopted across varying studies varied, with concomitant use of two or more psychotropic medications or use of four or more psychotropic medications at once being the most common and the most reliable, respectively. Regardless of type or current mood episode polarity of BD, prevalence rates up to 85% and 36% were found using the most permissive (two or more medications at once) and the most conservative (four or more) operative definitions for polypharmacy, respectively. Point prevalence prescription rates of one or more antidepressant or antipsychotic as part of a polypharmacy regimen occurred in up to 45% or 80% of the cases, respectively, according to the most permissive definition of polypharmacy. In contrast, lithium prescription rates ranged from 13% to 33% in BD patients receiving polypharmacy according to conservative and permissive definitions, possibly suggesting a reduced need for augmentation of combination strategies for those cases of BD with a favorable lifetime lithium response and/or long-lasting treatment as well as less likelihood of lithium response over the time most severe cases possibly exposed to a more complex polypharmacy overall.Limitations: “Apples and oranges” bias; publication bias for most recently introduced compounds.Conclusion: Polypharmacy is common among people with BD across varying type and mood episode phases of illness. Special population, including BD patients at high risk of familial load for suicidal behavior, solicit further research as well as the plausible “protective” role of lithium toward polypharmacy in BD. The PROSPERO registration number is CRD42014015084. Keywords: bipolar disorder, polypharmacy, prevalence, systematic review Fornaro MDe Berardis DKoshy ASPerna GValchera AVancampfort DStubbs BDove Medical PressarticleBipolar Disorderpolypharmacyprevalencesystematic review.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 719-735 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bipolar Disorder polypharmacy prevalence systematic review. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Bipolar Disorder polypharmacy prevalence systematic review. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Fornaro M De Berardis D Koshy AS Perna G Valchera A Vancampfort D Stubbs B Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
description	Michele Fornaro,1 Domenico De Berardis,2 Ann Sarah Koshy,3 Giampaolo Perna,4 Alessandro Valchera,5 Davy Vancampfort,6 Brendon Stubbs7,8 1New York Psychiatric Institute, Columbia University, New York, NY, USA; 2National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, Teramo, Italy; 3St. John’s National Academy of Health Sciences, Bangalore, India; 4Department of Clinical Neurosciences, Hermanas Hospitalarias - Villa San Benedetto Menni Hospital, FoRiPsi, 5Hermanas Hospitalarias, FoRiPsi Villa S. Giuseppe Hospital, Ascoli Piceno, Italy; 6Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium; 7Physiotherapy Department, South London and Maudsley NHS Foundation Trust, 8Health Service and Population Research Department, Institute of Psychiatry, King’s College London, London, UK Background: Uncertainty exists regarding the prevalence and clinical features associated with the practice of polypharmacy in bipolar disorder (BD), warranting a systematic review on the matter.Methods: Three authors independently searched major electronic databases from inception till September 2015. Articles were included that reported either qualitative or quantitative data about the prevalence and clinical features associated with polypharmacy in adult cases of BD.Results: The operative definitions of polypharmacy adopted across varying studies varied, with concomitant use of two or more psychotropic medications or use of four or more psychotropic medications at once being the most common and the most reliable, respectively. Regardless of type or current mood episode polarity of BD, prevalence rates up to 85% and 36% were found using the most permissive (two or more medications at once) and the most conservative (four or more) operative definitions for polypharmacy, respectively. Point prevalence prescription rates of one or more antidepressant or antipsychotic as part of a polypharmacy regimen occurred in up to 45% or 80% of the cases, respectively, according to the most permissive definition of polypharmacy. In contrast, lithium prescription rates ranged from 13% to 33% in BD patients receiving polypharmacy according to conservative and permissive definitions, possibly suggesting a reduced need for augmentation of combination strategies for those cases of BD with a favorable lifetime lithium response and/or long-lasting treatment as well as less likelihood of lithium response over the time most severe cases possibly exposed to a more complex polypharmacy overall.Limitations: “Apples and oranges” bias; publication bias for most recently introduced compounds.Conclusion: Polypharmacy is common among people with BD across varying type and mood episode phases of illness. Special population, including BD patients at high risk of familial load for suicidal behavior, solicit further research as well as the plausible “protective” role of lithium toward polypharmacy in BD. The PROSPERO registration number is CRD42014015084. Keywords: bipolar disorder, polypharmacy, prevalence, systematic review
format	article
author	Fornaro M De Berardis D Koshy AS Perna G Valchera A Vancampfort D Stubbs B
author_facet	Fornaro M De Berardis D Koshy AS Perna G Valchera A Vancampfort D Stubbs B
author_sort	Fornaro M
title	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
title_short	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
title_full	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
title_fullStr	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
title_full_unstemmed	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
title_sort	prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/0df8bd7f872d402b8a8f7a83207cb815
work_keys_str_mv	AT fornarom prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview AT deberardisd prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview AT koshyas prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview AT pernag prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview AT valcheraa prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview AT vancampfortd prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview AT stubbsb prevalenceandclinicalfeaturesassociatedwithbipolardisorderpolypharmacyasystematicreview
_version_	1718402022948995072

Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review

Ejemplares similares